HUMACYTE

Humacyte is a life sciences company committed to bringing first-in-class regenerative medicine products to the marketplace that will improve and save the lives of patients worldwide while transforming the practice of medicine. Specifically, they approached ICR to help educate investors about their revolutionary technology, the Human Acellular Vessel™ (HAV).

Imagine a readily available, “off-the-shelf ” bioengineered HAV that could replace a patients own blood vessel or create a new vascular access for patients who require dialysis, without requiring cells or tissue from the patient. Humacyte is making that happen. HAVs provide a game-changing solution for surgeons whose patients are dealing with vascular trauma. Partnering with a talented animation studio, we told that story to analysts, investors, and potential business partners by creating an “MOA” video that clearly explained how HAVs work and how Humacyte is changing the world.